Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Vidutolimod"'
Autor:
Julie Le Naour, Guido Kroemer
Publikováno v:
OncoImmunology, Vol 12, Iss 1 (2023)
ABSTRACTAccumulating evidence indicates that Toll-like receptor (TLR) agonists proficiently (re)instore cancer immunosurveillance as immunological adjuvants. So far, three TLR agonists have been approved by regulatory agencies for use in oncological
Externí odkaz:
https://doaj.org/article/3cf8d0ddd2c24965a615ff900bee09dc
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Marcelo V. Negrao, MD, Vassiliki A. Papadimitrakopoulou, MD, Andrew C. Price, MD, PhD, Alda L. Tam, MD, MBA, Muhammad Furqan, MD, Sandeep T. Laroia, MD, Erminia Massarelli, MS, MD, PhD, Jose Pacheco, MD, John V. Heymach, MD, PhD, Anne S. Tsao, MD, Gary V. Walker, MD, Lalit Vora, MD, David Mauro, MD, PhD, Heather Kelley, MA, James E. Wooldridge, MD, Arthur M. Krieg, MD, Jiaxin Niu, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 3, Pp 100423- (2023)
Introduction: Vidutolimod, a CpG-A TLR9 agonist, was investigated in a phase 1b study (CMP-001-003; ClinicalTrials.gov, NCT03438318) in combination with atezolizumab with and without radiation therapy (RT) in patients with advanced NSCLC. Methods: Pa
Externí odkaz:
https://doaj.org/article/375520c714da4dd0a0459208063f6fc7
Autor:
Shakoora A. Sabree, Caitlin D. Lemke-Miltner, Sue E. Blackwell, Chaobo Yin, Aaron Bossler, Kareem Ebeid, Aliasger K. Salem, George J. Weiner
Publikováno v:
Vaccines, Vol 9, Iss 9, p 982 (2021)
Vidutolimod, also known as CMP-001, is a virus-like particle composed of the Qβ bacteriophage coat protein encasing a TLR9 agonist. Vidutolimod injected intratumorally is showing promise in early phase clinical trials based on its ability to alter t
Externí odkaz:
https://doaj.org/article/166b965f36da434991cb4fa3e3371783
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Negrao MV; Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Papadimitrakopoulou VA; Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Price AC; Department of Radiology, Banner MD Anderson Cancer Center, Gilbert, Arizona., Tam AL; Department of Interventional Radiology, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, Texas., Furqan M; Department of Internal Medicine, Carver College of Medicine, University of Iowa Health Care, Iowa City, Iowa., Laroia ST; Department of Radiology, Division of Vascular and Interventional Radiology, Carver College of Medicine, University of Iowa Health Care, Iowa City, Iowa., Massarelli E; Department of Medical Oncology and Therapeutics Research, City of Hope, Duarte, California., Pacheco J; Department of Medicine-Medical Oncology, University of Colorado, Aurora, Colorado., Heymach JV; Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Tsao AS; Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Walker GV; Department of Radiology, Banner MD Anderson Cancer Center, Gilbert, Arizona., Vora L; Department of Diagnostic Radiology, City of Hope, Duarte, California., Mauro D; Checkmate Pharmaceuticals, Cambridge, Massachusetts., Kelley H; Checkmate Pharmaceuticals, Cambridge, Massachusetts., Wooldridge JE; Checkmate Pharmaceuticals, Cambridge, Massachusetts., Krieg AM; Checkmate Pharmaceuticals, Cambridge, Massachusetts., Niu J; Department of Medical Oncology, Banner MD Anderson Cancer Center, Gilbert, Arizona.
Publikováno v:
JTO clinical and research reports [JTO Clin Res Rep] 2022 Oct 26; Vol. 4 (3), pp. 100423. Date of Electronic Publication: 2022 Oct 26 (Print Publication: 2023).